ArticleADMET & DMPK2024
Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection.
Article in ADMET & DMPK, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy.Clinical and experimental medicine · 2025Review
- Nano-modified biosensors for detection of pathogenic diseases: The prospect of smart, multiplex and point-of-care testing.ADMET & DMPK · 2025Review
- Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia.ADMET & DMPK · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Chronic myeloid leukaemia (CML) is one of the most lethal types of leukaemia and can rapidly progress if not treated properly. Therefore, having an effective diagnostic strategy is crucial. Various methods are available for diagnosis, including electrochemical biosensors with aptamer bioreceptors. Experimental approach: In this study, we immobilized the KK1D04 aptamer on a screen-printed carbon electrode (SPCE) supported by CeO Key results: The developed aptasensor demonstrated good performance with a limit of detection (LOD) and limit of quantification (LOQ) of 16 cells/mL and 3,882 cells/mL, respectively, in the K562 cell concentration range of 10 Conclusion: The aptasensor in this study demonstrated the potential to detect K562 cells. These results could contribute to the advancement of point-of-care (POC) devices for the detection of CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.